Teva to Present at the Jefferies London Healthcare Conference
Rhea-AI Summary
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced that their President and CEO, Richard Francis, will deliver a presentation at the Jefferies London Healthcare Conference on November 19, 2024, at 8:30 AM GMT (3:30 AM ET). The presentation will be accessible via live webcast on Teva's Investor Relations website, with an archived version available within 24 hours after the live session concludes.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TEVA gained 1.52%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time).
To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| IR Contacts | Ran Meir | +1 (215) 591-8912 | |
| Yael Ashman | +972 (3) 914 8262 | ||
| Sanjeev Sharma | +1 (973) 658 2700 | ||
| PR Contacts | Kelley Dougherty Eden Klein | +1 (973) 832-2810 +972 (3) 906 2645 |
FAQ
When is Teva (TEVA) presenting at the Jefferies London Healthcare Conference 2024?
How can I watch Teva's (TEVA) presentation at the Jefferies London Healthcare Conference?
Will Teva's (TEVA) Jefferies Conference presentation be available for replay?
Who will represent Teva (TEVA) at the 2024 Jefferies London Healthcare Conference?
